Latest Breaking News On - Complete remission - Page 2 : comparemela.com

Actinium Pharma (ATNM) Reports Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients

Actinium Pharma (ATNM) Reports Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomGlasgow cityAvinash desaiActimaba national cancer instituteExchange commissionEuropean bone marrow transplant societyActinium pharmaceuticals incActinium pharmaceuticalsAntibody radiation conjugatesComplete remissionOvercomes high riskScottish event campusChief medical officerNorth africanAnnual meetingNational cancer institute

Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

Iomab-B significantly improved outcomes in TP53 positive patients with a median overall survival of 5.49 months versus 1.66 months in those not receiving Iomab-B (hazard ratio = 0.23, p-value=0.0002) in

United statesSan antonioAvinash desaiInternational blood marrow transplant researchAmerican society for transplantationActimaba national cancer instituteMarrow transplant researchExchange commissionActinium pharmaceuticals incInternational bloodPrnewswire actinium pharmaceuticals incCellular therapyAmerican societyComplete remissionChief medical officerIomabb phase

Actinium Pharma (ATNM) Highlights Improved Survival with Iomab-B

Actinium Pharma (ATNM) Highlights Improved Survival with Iomab-B
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan antonioAvinash desaiAmerican society for transplantationInternational bloodActinium pharmaceuticals incMarrow transplant researchActinium pharmaceuticalsCellular therapyAmerican societyComplete remissionChief medical officerIomabb phaseApamistamab improves outcomesTargeted myeloablative radiation usingApamistamab prior

Scalise returning to Washington next week with cancer in complete remission

House Majority Leader Steve Scalise (R-La.) is in “complete remission” after treatment for blood cancer and will return to Washington for votes next week after an extended absence, his office announced Thursday. “Leader Scalise has successfully completed his autologous stem cell treatment and has been medically cleared to resume travel,” Scalise’s office said in a…

United statesAlejandro mayorkasHouse majority leader steve scaliseHouse republicansHomeland security secretary alejandroSteve scaliseBlood cancerComplete remissionHouse majority leaderAlejandro mayorkasNext week

Actinium s Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia

NEW YORK - Actinium Pharmaceuticals, Inc. , a leader in the development of targeted radiotherapies, today highlighted four presentations at the 65th Annual American Society of Hematology Annual.

United statesSandesh sethAstellas pharmaActimaba national cancer instituteAmerican society of hematology annual meeting expositionOncology lg chem life sciencesActinium pharmaceuticals incExchange commissionHematology annual meetingMultiple high riskComplete remissionKarnofsky performance statusNational cancer instituteLife sciencesNews publishing